6-(3,6-Dimethoxy-2-nitrophenyl)-2-propylimidazo[2,1-b][1,3]thiazole-5-carbaldehyde | 851531-59-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 6-(3,6-Dimethoxy-2-nitrophenyl)-2-propylimidazo[2,1-b][1,3]thiazole-5-carbaldehyde
• CAS: 851531-59-4
• 化学式: C₁₇H₁₇N₃O₅S
• 分子量: 375.405
• InChiKey: DGULBPLAFSFJAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  127
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  6-(3,6-Dimethoxy-2-nitrophenyl)-2-propylimidazo[2,1-b][1,3]thiazole-5-carbaldehyde 、 肼甲酰亚胺酰胺一氯化氢 以 乙醇 为溶剂， 以60%的产率得到2-[(E)-[6-(3,6-dimethoxy-2-nitrophenyl)-2-propylimidazo[2,1-b][1,3]thiazol-5-yl]methylideneamino]guanidine;hydrochloride
  参考文献：
  名称：

  潜在的抗肿瘤药。37.由咪唑并[2，1-b]噻唑和新的杂环系统噻唑并[2′，3′：2，3]咪唑并[4，5-c]喹啉合成胍基hydr并具有抗肿瘤活性。

  摘要：

  本文报道了由咪唑并[2,1-b]噻唑和杂环新体系噻唑并[2'，3'：2,3]咪唑并[4,5-c]喹啉合成的新胍hydr及其抗肿瘤活性。这些化合物已在美国国家癌症研究所测试为潜在的抗肿瘤药物。研究了2-氯-6-（2,5-二甲氧基-4-硝基苯基）咪唑并[2,1-b]噻唑-5-甲醛的胍hydr的作用（41），发现其是抑制剂线粒体呼吸链复合物III的合成，能够诱导细胞株HT29和HL60凋亡。

  DOI：

  10.1021/jm040888s
• 作为产物：
  描述：

  2-bromo-1-(3,6-dimethoxy-2-nitrophenyl)ethan-1-one 在 三氯氧磷 作用下， 以 氯仿 、 丙酮 为溶剂， 生成 6-(3,6-Dimethoxy-2-nitrophenyl)-2-propylimidazo[2,1-b][1,3]thiazole-5-carbaldehyde
  参考文献：
  名称：

  潜在的抗肿瘤药。37.由咪唑并[2，1-b]噻唑和新的杂环系统噻唑并[2′，3′：2，3]咪唑并[4，5-c]喹啉合成胍基hydr并具有抗肿瘤活性。

  摘要：

  本文报道了由咪唑并[2,1-b]噻唑和杂环新体系噻唑并[2'，3'：2,3]咪唑并[4,5-c]喹啉合成的新胍hydr及其抗肿瘤活性。这些化合物已在美国国家癌症研究所测试为潜在的抗肿瘤药物。研究了2-氯-6-（2,5-二甲氧基-4-硝基苯基）咪唑并[2,1-b]噻唑-5-甲醛的胍hydr的作用（41），发现其是抑制剂线粒体呼吸链复合物III的合成，能够诱导细胞株HT29和HL60凋亡。

  DOI：

  10.1021/jm040888s

文献信息

• Imidazo[2,1-<i>b</i>]thiazole System: A Scaffold Endowing Dihydropyridines with Selective Cardiodepressant Activity
  作者：Roberta Budriesi、Pierfranco Ioan、Alessandra Locatelli、Sandro Cosconati、Alberto Leoni、Maria P. Ugenti、Aldo Andreani、Rosanna Di Toro、Andrea Bedini、Santi Spampinato、Luciana Marinelli、Ettore Novellino、Alberto Chiarini

  DOI：10.1021/jm070681+

  日期：2008.3.1

  The synthesis, characterization, and functional in vitro assays in cardiac tissues and smooth muscle (vascular and nonvascular) of a number of 4-imidazo[2,1-b]thiazole-1,4-dihydropyridines are reported. The binding properties for the novel compounds have been investigated and the interaction with the binding site common to other aryl-dihydropyridines has been demonstrated. Interestingly, the novel 4-aryl-dihydropyridines are L-type calcium channel blockers with a peculiar pharmacological behavior. Indeed, the imidazo[2,1-b]thiazole system is found to confer to the dihydropyridine scaffold an inotropic and/or chronotropic cardiovascular activity with a high selectivity toward the nonvascular tissue. Finally, molecular modeling studies were undertaken for the most representative compounds with the aim of describing the binding properties of the new ligands at molecular level and to rationalize the found structure-activity relationship data. Due to the observed pharmacological behavior of our compounds, they might be promising agents for the treatment of specific cardiovascular pathologies such as cardiac hypertrophy and ischemia.
• Ligand Based Approach to L-Type Calcium Channel by Imidazo[2,1-<i>b</i>]thiazole-1,4-Dihydropyridines: from Heart Activity to Brain Affinity
  作者：Alessandra Locatelli、Sandro Cosconati、Matteo Micucci、Alberto Leoni、Luciana Marinelli、Andrea Bedini、Pierfranco Ioan、Santi Mario Spampinato、Ettore Novellino、Alberto Chiarini、Roberta Budriesi

  DOI：10.1021/jm301839q

  日期：2013.5.23

  The synthesis, characterization, and functional in vitro assay in cardiac and smooth muscle (vascular and nonvascular) of a series of 4-imidazo[2,1-b]thiazole-1,4-dihydropyridines are reported. To define the calcium blocker nature of the imidazo[2,1-b]thiazole-1,4-DHPs and their selectivity on Ca(v)1.2 and Ca(v)1.3 isoforms, we performed binding studies on guinea pig atrial and ventricular membranes on intact cells expressing the cloned Ca(v)1.2a subunit and on rat brain cortex. To get major insights into the reasons for the affinity for Ca(v)1.2 and/or Ca(v)1.3, molecular modeling studies were also undertaken. Some physicochemical and pharmacokinetic properties of selected compounds were calculated and compared. All the biological data collected and reported herein allowed us to rationalize the structure-activity relationship of the 4-imidazo[2,1-b]thiazole-1,4-DHPs and to identify which of these enhanced the activity at the central level.